Taysha Gene Therapies, Inc. (TSHA): Cash & Equivalents
$319.77M
As of 2025-12-31
$455.41M
As of 2026-06-30
+53.8%
3-year compound annual growth
+4.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $319.77M | +130.0% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $139.04M | -3.4% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $143.94M | +63.8% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $87.88M | -41.1% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $149.10M | -40.7% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $251.25M | n/a | 2022-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $152.41M | -14.7% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $84.02M | -32.4% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $17.97M | n/m |
Compare TSHA, CRIS, ACOG, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗